<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=896170837107954&amp;ev=PageView&amp;noscript=1">

NeoTract Inc. Announces Cigna Coverage for the UroLift® System for Enlarged Prostate

PLEASANTON, Calif.– May 11, 2017 – NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, today announced that Cigna, a global health service company that provides insurance for over 14 million Americans, has established coverage for the UroLift® System for the treatment of enlarged prostate, or benign prostatic hyperplasia (BPH).

Read More

NeoTract Inc. Announces Presentations of Multiple Clinical Studies Featuring Five-Year Data from Pivotal Randomized Trial of UroLift® System at American Urological Association 2017 Meeting

PLEASANTON, Calif.– May 8, 2017 – NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, today announced activities planned for the 112th American Urological Association Annual Meeting taking place May 12-16 at the Boston Convention and Exhibition Center in Boston, Mass.

Read More

NeoTract Inc. Receives #Gamechanger Award for Innovation

PLEASANTON, Calif.– April 13, 2017 – NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, announced today that the company has been recognized with the Innovation Tri-Valley Leadership Group’s #Gamechanger Award.

Read More

NeoTract’s Minimally Invasive UroLift® System for Enlarged Prostate Now Shown to be Durable Through Five Years: Results from Pivotal L.I.F.T. Randomized Study Presented

PLEASANTON, Calif. and LONDON – March 27, 2017 – NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, today announced five-year follow-up data from the pivotal, randomized L.I.F.T. IDE study, which evaluated the safety and effectiveness of the company’s novel UroLift® System in patients with symptomatic benign prostatic hyperplasia (BPH).

Read More

Revolutionary UroLift® System Launches in Ireland

PLEASANTON, CA, US March 23, 2017 - NeoTract, Inc., announced today that the largest private health insurer in Ireland, Vhi Group, is to reimburse the minimally invasive UroLift System in the country - making a day case surgical treatment requiring no cutting, heating or removal of tissue available for the first time to thousands of Irish men with a urological condition described as very common in older males.
 
The UroLift System treats symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH) in men. Delivered during a minimally-invasive procedure, the UroLift implants act like window curtain tie-backs to hold the lobes of an enlarged prostate open. Patients typically recover from the procedure quickly, and often return to their normal routines with minimal downtime.

Read More

NeoTract’s UroLift® System Featured in the American Urological Association’s Urology Residents BPH/LUTS Training Program

PLEASANTON, Calif. – March 21, 2017 – NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, announced today that the company’s UroLift System for the treatment of enlarged prostate, or benign prostatic hyperplasia (BPH), was featured in an American Urological Association (AUA) training event that took place last week at the AUA headquarters in Linthicum, Md. 

Read More

NeoTract Convenes Leading Urologists for Summit on Treating Benign Prostatic Hyperplasia (BPH) and Lower Urinary Tract Symptoms

PLEASANTON, Calif. – NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, recently hosted more than 60 urologists from around the country to review clinical data and share best practices for using the UroLift® System to improve the care of patients with enlarged prostate, or benign prostatic hyperplasia (BPH). Highlights from the meeting included robust data presentations and the designation of three new UroLift Centers of Excellence from Jamestown, New York; Pittsburgh, Penn., and Fullerton, Calif.

Read More

NeoTract Inc. to Present at the 35th Annual J.P. Morgan Healthcare Conference

PLEASANTON, Calif. – NeoTract, Inc., a medical device company that markets the UroLift System for treating enlarged prostate, today announced that it will present at the 35th Annual J.P. Morgan Healthcare Conference. Dave Amerson, President and CEO of NeoTract, is scheduled to present on Monday, January 9th at 1:30pm PT at the Westin St. Francis in San Francisco, CA.

Read More

NeoTract’s UroLift System Featured in Five Presentations at World Congress of Endourology Meeting in South Africa

PLEASANTON, Calif. – NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, today announced presentations at the 34th World Congress of Endourology (WCE) in Cape Town, South Africa, featuring the UroLift® System for the treatment of enlarged prostate, or benign prostatic hyperplasia (BPH).

Read More

NeoTract, Inc. Announces Medicare Administrative Contractor First Coast Service Options (FCSO) Coverage for the UroLift® System for BPH

PLEASANTON, Calif. –  NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, today announced that First Coast Service Options, Inc., the Medicare Administrative Contractor (MAC) covering Florida, Puerto Rico and the U.S. Virgin Islands, has established coverage for the UroLift® System for the treatment of enlarged prostate, or benign prostatic hyperplasia (BPH).

Read More